Prefusion RSV F proteins and their use
US10858400B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 26, 2017 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Nov 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18534
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.